McMillion Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $1.55M | Sell |
42,135
-1,480
| -3% | -$57.6K | 1.38% | 23 |
|
|
2023
Q1 | $1.78M | Sell |
43,615
-4,426
| -9% | -$191K | 1.68% | 19 |
|
|
2022
Q4 | $2.46M | Sell |
48,041
-725
| -1% | -$34.8K | 2.23% | 12 |
|
|
2022
Q3 | $2.13M | Sell |
48,766
-3,395
| -7% | -$165K | 1.98% | 12 |
|
|
2022
Q2 | $2.73M | Sell |
52,161
-9,183
| -15% | -$468K | 2.28% | 10 |
|
|
2022
Q1 | $3.18M | Sell |
61,344
-5,825
| -9% | -$302K | 1.97% | 11 |
|
|
2021
Q4 | $3.97M | Buy |
67,169
+767
| +1% | +$38K | 2.14% | 10 |
|
|
2021
Q3 | $2.86M | Sell |
66,402
-520
| -0.8% | -$23K | 1.68% | 16 |
|
|
2021
Q2 | $2.62M | Sell |
66,922
-3,434
| -5% | -$134K | 1.43% | 23 |
|
|
2021
Q1 | $2.55M | Buy |
70,356
+1,159
| +2% | +$41.2K | 1.49% | 23 |
|
|
2020
Q4 | $2.55M | Sell |
69,197
-4,306
| -6% | -$158K | 1.55% | 24 |
|
|
2020
Q3 | $2.56M | Sell |
73,503
-4,290
| -6% | -$150K | 1.92% | 19 |
|
|
2020
Q2 | $2.41M | Sell |
77,793
-20,308
| -21% | -$690K | 1.59% | 25 |
|
|
2020
Q1 | $3.04M | Sell |
98,101
-4,604
| -4% | -$157K | 2.07% | 16 |
|
|
2019
Q4 | $3.82M | Sell |
102,705
-1,129
| -1% | -$40.2K | 1.84% | 18 |
|
|
2019
Q3 | $3.54M | Sell |
103,834
-738
| -0.7% | -$26.8K | 1.88% | 19 |
|
|
2019
Q2 | $4.3M | Sell |
104,572
-452
| -0.4% | -$17.9K | 2.27% | 12 |
|
|
2019
Q1 | $4.23M | Buy |
105,024
+2,025
| +2% | +$81.1K | 2.29% | 14 |
|
|
2018
Q4 | $4.27M | Buy |
102,999
+777
| +0.8% | +$32.3K | 2.75% | 10 |
|
|
2018
Q3 | $4.27M | Buy |
102,222
+1,322
| +1% | +$50.9K | 2.28% | 12 |
|
|
2018
Q2 | $3.47M | Buy |
100,900
+230
| +0.2% | +$7.86K | 1.97% | 19 |
|
|
2018
Q1 | $3.39M | Sell |
100,670
-2,269
| -2% | -$78K | 2% | 17 |
|
|
2017
Q4 | $3.54M | Buy |
102,939
+2,103
| +2% | +$71.7K | 2.12% | 18 |
|
|
2017
Q3 | $3.42M | Buy |
100,836
+195
| +0.2% | +$6.27K | 2.24% | 17 |
|
|
2017
Q2 | $3.21M | Buy |
100,641
+316
| +0.3% | +$9.96K | 2.15% | 19 |
|
|
2017
Q1 | $3.26M | Sell |
100,325
-1,128
| -1% | -$35.6K | 2.21% | 20 |
|
|
2016
Q4 | $3.13M | Sell |
101,453
-185
| -0.2% | -$5.65K | 2.23% | 20 |
|
|
2016
Q3 | $3.27M | Buy |
101,638
+3,314
| +3% | +$111K | 2.44% | 17 |
|
|
2016
Q2 | $3.29M | Sell |
98,324
-2,156
| -2% | -$68.8K | 2.54% | 15 |
|
|
2016
Q1 | $2.83M | Buy |
100,480
+382
| +0.4% | +$10.9K | 2.1% | 21 |
|
|
2015
Q4 | $3.07M | Sell |
100,098
-1,113
| -1% | -$35K | 2.3% | 19 |
|
|
2015
Q3 | $3.02M | Sell |
101,211
-8,998
| -8% | -$289K | 2.33% | 15 |
|
|
2015
Q2 | $3.51M | Sell |
110,209
-3,679
| -3% | -$120K | 2.18% | 17 |
|
|
2015
Q1 | $3.76M | Sell |
113,888
-4,026
| -3% | -$128K | 2.24% | 19 |
|
|
2014
Q4 | $3.48M | Buy |
117,914
+258
| +0.2% | +$7.4K | 2% | 19 |
|
|
2014
Q3 | $3.3M | Sell |
117,656
-196
| -0.2% | -$5.5K | 1.94% | 23 |
|
|
2014
Q2 | $3.32M | Buy |
117,852
+2,157
| +2% | +$61.5K | 1.92% | 22 |
|
|
2014
Q1 | $3.53M | Sell |
115,695
-838
| -0.7% | -$25K | 2.15% | 18 |
|
|
2013
Q4 | $3.39M | Sell |
116,533
-2,046
| -2% | -$59.5K | 2.06% | 20 |
|
|
2013
Q3 | $3.23M | Sell |
118,579
-1,311
| -1% | -$35.7K | 2.31% | 19 |
|
|
2013
Q2 | $3.19M | Buy |
+119,890
| New | +$3.31M | 2.35% | 20 |
|
Other funds holding PFE
McMillion Capital Management's PFE Position: Q2 2023 in Review
McMillion Capital Management reduced its Pfizer (PFE) stake by 3.4% in Q2 2023, selling an estimated $57.6K and leaving 42,135 shares worth $1.55M. The position accounts for 1.38% of the portfolio, ranked #23.
McMillion Capital Management first reported a position in PFE in Q2 2013 and has held it in 41 quarters since. The position peaked at $4.3M in Q2 2019. 3,042 funds tracked by Wall St. Rank hold PFE as of Q2 2023.
- McMillion Capital Management held 42,135 shares of Pfizer worth $1.55M as of Q2 2023.
- McMillion Capital Management sold 1,480 Pfizer shares in Q2 2023, an estimated $57.6K.
- Pfizer made up 1.38% of McMillion Capital Management's portfolio in Q2 2023, its #23 holding.
- McMillion Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 41 quarters since.
- McMillion Capital Management's Pfizer position peaked at $4.3M in Q2 2019.
- 3,042 funds tracked by Wall St. Rank held Pfizer as of Q2 2023.
Based on McMillion Capital Management's 13F filing for Q2 2023, filed 8 Aug 2023.